- Home
- ATOS vs HLVX Comparison
ATOS vs HLVX Comparison
Compare ATOS & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- HLVX
- Stock Information
- Founded
- ATOS 2009
- HLVX 2020
- Country
- ATOS United States
- HLVX United States
- Employees
- ATOS N/A
- HLVX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- HLVX Health Care
- Exchange
- ATOS Nasdaq
- HLVX Nasdaq
- Market Cap
- ATOS 96.8M
- HLVX 83.7M
- IPO Year
- ATOS 2012
- HLVX 2022
- Fundamental
- Price
- ATOS $0.74
- HLVX $1.86
- Analyst Decision
- ATOS Strong Buy
- HLVX Hold
- Analyst Count
- ATOS 3
- HLVX 5
- Target Price
- ATOS $7.13
- HLVX $2.33
- AVG Volume (30 Days)
- ATOS 714.9K
- HLVX 287.5K
- Earning Date
- ATOS 05-12-2025
- HLVX 05-08-2025
- Dividend Yield
- ATOS N/A
- HLVX N/A
- EPS Growth
- ATOS N/A
- HLVX N/A
- EPS
- ATOS N/A
- HLVX N/A
- Revenue
- ATOS N/A
- HLVX N/A
- Revenue This Year
- ATOS N/A
- HLVX N/A
- Revenue Next Year
- ATOS N/A
- HLVX N/A
- P/E Ratio
- ATOS N/A
- HLVX N/A
- Revenue Growth
- ATOS N/A
- HLVX N/A
- 52 Week Low
- ATOS $0.55
- HLVX $1.34
- 52 Week High
- ATOS $1.81
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- ATOS 58.85
- HLVX 66.30
- Support Level
- ATOS $0.59
- HLVX $1.64
- Resistance Level
- ATOS $0.67
- HLVX $1.75
- Average True Range (ATR)
- ATOS 0.06
- HLVX 0.11
- MACD
- ATOS 0.01
- HLVX 0.04
- Stochastic Oscillator
- ATOS 88.47
- HLVX 100.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.